Theodora Akbulut

Experience

• 

  Duzen Laboratories Group

  Jul 2016 - Sept 2016

  Research Intern
• 

  Yeditepe University Hospitals

  Jul 2017 - Nov 2017

  Research Intern
• 

  Istanbul Bilgi University

  Jun 2018 - May 2019

  Associate Researcher

  • Continue to work on my thesis project with Bahcesehir University School of Medicine. Design more detailed pharmacophore models that bind effectively and specifically to the ligand CD112 (Nectin-2) which is a potential target for breast and ovarian cancer.• Abstract accepted by 6th International BAU Drug Design Congress committee. Abstract and poster published in the platform of congress and poster presented on last day of congress with among other candidates.• Apply and learn new software programs, statistical techniques like MGLTools, Amber-MD,GROMACS, Schrödinger to be able to see the interactions between proteins in more detailed versions to give the best drug candidates with high Auto Dock results, including simulations results.• The residues Thr55, Gln56, Tyr113, Pro114 and Asp115 on TIGIT at the TIGIT:CD112 interface were found to be important in binding. Triple combinations of these important residues were used to construct sever al pharmacophores which used later to screen the ZINC database. More than 2000 small molecules were retrieved from the ZINC database using the pharmacophores. These molecules were docked to the CD112 using Autodock 4.2 program. Analysis of the docking results revealed several micromolar binders. As conclusion, using computational methods we have discovered several drug candidates that bind to CD112 at micromolar level. Show less

• 

  Bristol Myers Squibb

  Jan 2020 - now

  • LIMS Manager, CTDO QC Systems

    Sept 2023 - now

  • Senior LIMS Specialist, CTDO LIMS GLOBAL

    May 2022 - Sept 2023

  • QC Associate Scientist, CAR T Bioanalytical

    Jun 2021 - May 2022

  • CAR T Quality Control Analyst

    Jan 2020 - Jun 2021